Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales

LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), known as Merck in the U.S. and Canada, through a wholly owned subsidiary or a nominee, today announced that the High Court of Justice of England and Wales has approved the proposal for MSD to acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion (the “Transaction”).

GlobeNewsWire • Oct 6, 2025

Shareholders of Verona Pharma Approve Proposed Acquisition by Merck

LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by Merck & Co., Inc. (NYSE: MRK) (“Merck”) through a wholly owned subsidiary or a nominee, today announced that its shareholders have approved the proposal for Merck to acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion (the “Transaction”).

GlobeNewsWire • Sep 24, 2025

Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025

Posters support Ohtuvayre ® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population

GlobeNewsWire • Sep 16, 2025

All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy

Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Aug 12, 2025

Investing $2,000 in Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth Nearly $135,000 Today

Investing in index funds is a safe way to grow your portfolio over the years. But there's a huge advantage to picking individual stocks: Your returns can be massive and life-changing.

The Motley Fool • Jul 31, 2025

Volatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA Stocks

Shield your portfolio from market swings with low-beta picks like VIPS, GDS, FUTU and VRNA, each showing strong momentum.

Zacks Investment Research • Jul 30, 2025

Weathering Market Uncertainty? Bet on VIPS, ALKT, FUTU & VRNA Now

In a volatile market, low-beta picks like VIPS, ALKT, FUTU and VRNA offer investors stability with solid upside potential.

Zacks Investment Research • Jul 16, 2025

What Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?

Does Verona Pharma PLC American Depositary Share (VRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Jul 15, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Verona Pharma plc (NASDAQ: VRNA)

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Verona Pharma plc (NASDAQ: VRNA ) related to its sale to Merck Sharp & Dohme LLC for $107.00 per American Depository Shares. Is it a fair deal?

GlobeNewsWire • Jul 14, 2025

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verona Pharma plc (NasdaqGM: VRNA) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Verona will receive $107.00 in cash for each share of American Depository Share that they own. KSF is seeking to determine whether this consideration and the process.

Business Wire • Jul 13, 2025